White blood cell concentration correlates with increased concentrations of IL-1ra and improvement in WOMAC pain scores in an open-label safety study of autologous protein solution

William King, Walter van der Weegen, Rogier Van Drumpt, Hans Soons, Krista Toler, Jennifer Woodell-May, William King, Walter van der Weegen, Rogier Van Drumpt, Hans Soons, Krista Toler, Jennifer Woodell-May

Abstract

Background: There has been debate on which blood components should be included in autologous therapies. Autologous Protein Solution (APS) is a unique blood-derived therapy composed of concentrated white blood cells, platelets, and plasma to contain high concentrations of anti-inflammatory cytokines and anabolic growth factors to potentially address osteoarthritis. The primary aim of the exploratory secondary analysis was to identify characteristics of an Autologous Protein Solution (APS) that may correlate with improved Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and OMERACT-OARSI responder status after treatment of subjects with an intra-articular injection of APS.

Methods: Eleven subjects were enrolled in a pilot study of a single intra-articular injection of APS in subjects with knee osteoarthritis. Two APS kits were processed per patient. The output of the first APS kit was injected intra-articularly. White blood cell (WBC) and cytokine concentrations were measured from the output of the second APS kit. WOMAC surveys were completed at baseline and at follow up visits. Linear regression analyses were performed on the blood components of APS with subject outcomes. Anderson-Darling analysis was used to determine whether the cytokine concentrations in whole blood and APS had a normal distribution. Either paired t-test analyses or Wilcoxon signed-rank analyses were performed for normal and non-parametrically distributed data, respectively.

Results: The WBC concentration in APS was significantly (p < 0.05) and strongly (R(2) > 0.7) correlated with IL-1ra in APS but not significantly correlated with IL-1β. The ratio of IL-1ra to IL-1β in APS was significantly correlated with improved WOMAC pain scores one week and six months post-injection. 85.7 % of subjects whose APS had a IL-1ra:IL-1β ratio greater than 1000 or a WBC count greater than 30 k/μl were OMERACT-OARSI responders six months post-injection.

Conclusions: The correlations between the IL-1ra:IL-1β ratio and WBC concentration in a subject's APS and their WOMAC pain scores and classification as OMERACT-OARSI responders suggest the potential utility of these characteristics as diagnostic markers. Additional studies are ongoing to determine whether APS is safe and effective and to further evaluate the relationship between APS composition and clinical outcomes.

Trial registration: ( NCT01773226 ).

Keywords: Function; Growth factor; IL-1ra; Inflammation; Pain; Platelet-rich plasma.

References

    1. Arden NK. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323–340. doi: 10.1016/S1359-6101(02)00020-5.
    1. Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl. 2002;65:16–21.
    1. Arend WP, Malyak M, Smith MF, Jr, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK. Binding of IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol. 1994;153:4766–4774.
    1. Assirelli E, Filardo G, Mariani E, Kon E, Roffi A, Vaccaro F, Marcacci M, Facchini A, Pulsatelli L. Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surg Sports Traumatol Arthrosc. 2014;23:2690–2703. doi: 10.1007/s00167-014-3113-3.
    1. Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, Desiderio MA. Molecular basis of anti-inflammatory action of platelet rich plasma on human chondrocytes: mechanisms of NF-kB inhibition via HGF. J Cell Physiol. 2010;225:757–766. doi: 10.1002/jcp.22274.
    1. Bertone AL, Ishihara A, Zekas LJ, Wellman ML, Lewis KB, Schwarze R, Barnaba A, Schmall ML, Kanter PM, Genovese RL. Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses. Am J Vet Res. 2014;75:141–151. doi: 10.2460/ajvr.75.2.141.
    1. Braun H, Kim H, Chu C, Dragoo J. The effect of platelet-rich plasma formulations and blood products on human synoviocytes implications for intra-articular injury and therapy. Am J Sports Med. 2014;42:1204–1210. doi: 10.1177/0363546514525593.
    1. Browning SR, Weiser AM, Woolf N, Golish SR, Sangiovanni TP, Scuderi GJ, Carballo C, Hanna LS. Platelet-rich plasma increases matrix metalloproteinases in cultures of human synovial fibroblasts. J Bone Joint Surg Am. 2012;94:e1721–e1727. doi: 10.2106/JBJS.K.01501.
    1. Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol. 2013;9:400–410. doi: 10.1038/nrrheum.2013.44.
    1. Cross JA, Cole BJ, Spatny KP, Sundman E, Romeo AA, Nicholson GP, Wagner B, Fortier LA. Leukocyte-reduced platelet-rich plasma normalizes matrix metabolism in torn human rotator cuff tendons. Am J Sports Med. 2015;43:2898–2906. doi: 10.1177/0363546515608157.
    1. Filardo G, Kon E, Roffi A, Di Matteo B, Merli ML, Marcacci M. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg Sports Traumatol Arthrosc. 2013;23:2459–2474. doi: 10.1007/s00167-013-2743-1.
    1. Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep. 2000;2:459–465. doi: 10.1007/s11926-000-0021-y.
    1. Jordan M, Otterness IG, Ng R, Gessner A, Rollinghoff M, Beuscher H. Neutralization of endogenous IL-6 suppresses induction of IL-1 receptor antagonist. J Immunol. 1995;154:4081–4090.
    1. King WJ and Woodell-May J (2013) Effect of leukocytes on the composition of cytokines and growth factors in two autologous preparations. Published in the Proceedings for the International Cartilage Repair Society Meeting.
    1. King WJ and Woodell-May JE (2014) Comparison of the cellular and cytokine concentrations in the output of the autologous protein solution, orthokine, and onoccomed 2 device systems. Published in the Proceedings of the Orthopaedic Research Society Meeting.
    1. King WJ and Woodell-May JE (2014) A simple method to correlate the concentration of an anti-inflammatory cytokine with white blood cells in an autologous protein solution. Orthopaedic Research Society Spring 2014 Meeting.
    1. Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging. 2010;27:95–115. doi: 10.2165/11319950-000000000-00000.
    1. Matuska A, O’Shaughnessey KM, King WJ, Woodell-May JE. Autologous solution protects bovine cartilage explants from IL-1α- and TNFα- induced cartilage degradation. J Orthop Res. 2013;31:1929–1935. doi: 10.1002/jor.22464.
    1. Montaseri A, Busch F, Mobasheri A, Buhrmann C, Aldinger C, Rad JS, Shakibaei M. IGF-1 and PDGF-bb suppress IL-1β-induced cartilage degradation through down-regulation of NF-κβ signaling: involvement of Src/PI-3 K/AKT pathway. PLoS One. 2011;6 doi: 10.1371/journal.pone.0028663.
    1. O’Shaughnessey KM, Panitch A, Woodell-May JE. Blood-derived anti-inflammatory protein solution blocks the effect of IL-1β on human macrophages in vitro. Inflamm Res. 2011;60:929–936. doi: 10.1007/s00011-011-0353-2.
    1. O’Shaughnessey K, Matuska A, Hoeppner J, Farr J, Klaassen M, Kaeding C, Lattermann C, King W, Woodell-May J. Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors. J Orthop Res. 2014;32:1349–1355. doi: 10.1002/jor.22671.
    1. Pham T, van der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol. 2003;30:1648–1654.
    1. Sanchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants. 2003;18:93–103.
    1. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol. 1996;14:155–162.
    1. Sheth U. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J Bone Joint Surg Am. 2012;94:298–307. doi: 10.2106/JBJS.K.00154.
    1. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39:2135–2140. doi: 10.1177/0363546511417792.
    1. Vasina EM, Cauwenberghs S, Feijge MA, Heemskerk JW, Weber C, Koenen RR. Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis. 2011;2:1–10. doi: 10.1038/cddis.2011.115.
    1. Wehling P, Moser C, Frisbie D, McIlwraith CW, Kawcak CE, Krauspe R, Reinecke JA. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs. 2007;21:323–332. doi: 10.2165/00063030-200721050-00004.
    1. Woodell-May J, Matuska A, Oyster M, Welch Z, O’Shaughnessey K, Hoeppner J. Autologous protein solution inhibits MMP-13 production by IL-1β and TNFα-stimulated human articular chondrocytes. J Orthop Res. 2011;29:1320–1326. doi: 10.1002/jor.21384.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi